Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Novartis (SWX:NOVN) has drawn attention after recent share price moves, with the stock last closing at CHF 118.82. Investors are weighing this level against its recent returns and underlying earnings profile.
See our latest analysis for Novartis.
The recent 1 day share price return of 1.19% to CHF 118.82 comes after a mixed short term patch, with a 2.41% 7 day share price decline but a 9.51% year to date share price gain and a 5 year total shareholder return of 86.99%, indicating that long term holders have seen materially stronger results than short term traders.
If this kind of steady compounding appeals to you, it may be worth widening your search to companies with resilient leadership profiles by reviewing the 101 top founder-led companies
With Novartis trading at CHF 118.82, close to a CHF 120.43 analyst price target but with an estimated intrinsic value gap, you have to ask: is this a genuine value opportunity, or is future growth already priced in?
The most followed narrative assigns Novartis a fair value of CHF 121.41, slightly above the last close at CHF 118.82. This suggests a small valuation gap built on detailed earnings and revenue assumptions, rather than short term trading moves.
Novartis’ robust pipeline and rapid regulatory progress in advanced therapies (including biologics, gene, and cell therapies) positions the company to benefit from emerging healthcare technologies, with the potential to affect future earnings and margin performance as new high-value products launch.
Want to see what kind of revenue path, margin uplift, and future earnings power are reflected in that fair value, and how long term forecasts tie it all together? The narrative lays out the growth rates, profitability shift and valuation multiple that underpin CHF 121.41, along with how analysts are weighing higher profitability against a more measured outlook for top line expansion.
Result: Fair Value of CHF 121.41 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, there is still meaningful risk that the loss of exclusivity for key drugs and rising global pricing pressure, particularly in China and Europe, could challenge this outlook.
Find out about the key risks to this Novartis narrative.
All of this paints a mixed picture, so it makes sense to look through the numbers and sentiment yourself rather than rely on one headline view. To see how the upside and downside stack up side by side, check the 5 key rewards and 1 important warning sign
If you stop with one stock, you risk missing opportunities that could fit your goals even better, so keep your watchlist fresh with a few focused screens.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVN.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com